Almost everyone who starts a GLP-1 medication for weight loss hears the same two things: that it works, and that it might make you feel unwell for a while. Both are true, and neither is very useful on its own. What patients actually want to know is more specific — how common is nausea, really? How long does it last? Is what I'm feeling normal, or is it the thing I'm supposed to call someone about?

This guide answers those questions using the current FDA-approved prescribing information for semaglutide (Wegovy) and tirzepatide (Zepbound), plus the clinical guidance physicians actually use to manage these medications. It's written for people in Tarzana and across the San Fernando Valley who are either considering a GLP-1 or already on one and want a clearer picture than a forum thread can give them.

Why GLP-1 medications cause side effects in the first place

GLP-1 receptor agonists work partly by slowing how quickly the stomach empties and by acting on appetite signaling in the brain. That delayed gastric emptying is not a malfunction — it's part of the mechanism that makes you feel full sooner and stay full longer. But the same effect is why the most common side effects are almost all digestive: nausea, constipation, diarrhea, reflux, burping, bloating.

Tirzepatide adds a second mechanism. It's a dual GIP and GLP-1 receptor agonist, which is part of why its dosing and side-effect profile look somewhat different from semaglutide's. If you're weighing the two, our detailed comparison of tirzepatide and semaglutide covers how they differ in practice.

How common are GLP-1 side effects? What the trials actually showed

Numbers matter here, because “common side effect” means very different things to different people. The figures below come directly from the FDA prescribing information for each drug, comparing the medication against placebo in adults treated for weight reduction.

Semaglutide (Wegovy injection, 2.4 mg weekly)

• Nausea: 44% on semaglutide vs. 16% on placebo
• Diarrhea: 30% vs. 16%
• Vomiting: 24% vs. 6%
• Constipation: 24% vs. 11%
• Abdominal pain: 20% vs. 10%
• Headache: 14% vs. 10%
• Fatigue: 11% vs. 5%
• Hair loss: 3% vs. 1%

Across those trials, 6.8% of patients on semaglutide stopped treatment because of a side effect, compared with 3.2% on placebo. The most frequent reasons for stopping were nausea (1.8%), vomiting (1.2%), and diarrhea (0.7%).

Tirzepatide (Zepbound, 5–15 mg weekly)

• Nausea: 25–29% depending on dose, vs. 8% on placebo
• Diarrhea: 19–23% vs. 8%
• Vomiting: 8–13% vs. 2%
• Constipation: 11–17% vs. 5%
• Abdominal pain: 9–10% vs. 5%
• Injection site reactions: 6–8% vs. 2%
• Hair loss: 4–5% vs. 1%

Discontinuation due to adverse reactions ran 4.8%, 6.3%, and 6.7% at the 5 mg, 10 mg, and 15 mg doses respectively, versus 3.4% on placebo — and the label notes that most people who stopped did so in the first few months, because of digestive symptoms.

How to read those numbers

Three things stand out. First, nausea is genuinely common — roughly two in five people on semaglutide report it at some point. Second, the placebo columns are not zero, which means a meaningful share of these symptoms happen to people who aren't on the drug at all. Third, and most importantly: the overwhelming majority of people who experience side effects keep taking the medication. Roughly 93–95% of trial participants did not stop.

How long do GLP-1 side effects last?

Digestive side effects cluster in two windows: the first few weeks after starting, and the days following each dose increase. Both drugs are designed to be titrated slowly for exactly this reason — semaglutide injection starts at 0.25 mg weekly and steps up roughly every four weeks; tirzepatide starts at 2.5 mg weekly and increases in 2.5 mg increments after at least four weeks.

For most people, symptoms soften as the body adapts to a given dose. The clinical literature on managing these medications is consistent on the practical implication: if nausea or vomiting persists despite conservative measures, the answer is usually to hold the current dose longer — often an additional two to four weeks — rather than push forward on schedule. Escalating more slowly is associated with less nausea.

What actually helps with GLP-1 side effects

These are the strategies used in clinical practice. None of them require anything exotic.

Eat differently, not just less

• Smaller, more frequent meals instead of two or three large ones
• Stop eating at the first sign of fullness rather than finishing the plate
• Reduce high-fat and very greasy foods, which empty from the stomach slowest
• Go easy on high-sugar foods and drinks, which tend to worsen nausea and loose stools
• Prioritize protein — this matters for hunger control and for preserving lean mass, which we cover in depth in our guide to protecting muscle during GLP-1 weight loss

Stay ahead of hydration

Appetite suppression reduces thirst cues as well as hunger cues, and people routinely drink less without noticing. Both labels carry a warning about acute kidney injury caused by volume depletion — the mechanism is dehydration from nausea, vomiting, or diarrhea, not a direct toxic effect on the kidney. Consistent fluid intake is genuinely protective, not just general advice.

Treat constipation and diarrhea directly

Constipation is often the symptom people tolerate longest without mentioning it, and it's frequently the easiest to address — with fluids, fiber, movement, and, where appropriate, a stool softener or osmotic laxative. Diarrhea can be managed with dietary adjustment and, in some cases, an antidiarrheal. Both are worth raising at a follow-up visit rather than enduring.

Slow down the schedule

The titration schedule is a maximum pace, not a requirement. A provider who is paying attention will hold a dose, or step back to a previous one, when tolerability calls for it. This is one of the clearest arguments for supervised care over a fill-and-forget prescription.

The side effects that are not “just part of it”

Most GLP-1 side effects are uncomfortable rather than dangerous. A smaller set are not, and these are the ones worth knowing by name. This is general education, not a substitute for the Medication Guide that comes with your prescription or for advice from your own provider.

Thyroid C-cell tumors (boxed warning)

Both semaglutide and tirzepatide carry the FDA's most serious warning category. In rodents, these medications cause thyroid C-cell tumors; whether that translates to humans is not known, and the human relevance has not been determined. Both drugs are contraindicated — meaning they should not be used at all — in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Symptoms to report: a lump or mass in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.

Acute pancreatitis

Reported with GLP-1 receptor agonists including both of these medications. The hallmark is persistent, severe abdominal pain that may radiate to the back, with or without vomiting. Both labels instruct that the medication be discontinued if pancreatitis is suspected. This is an urgent evaluation, not a wait-and-see symptom.

Gallbladder disease

Acute gallbladder disease has occurred in clinical trials with both drugs. Rapid weight loss of any kind raises gallstone risk, so this isn't unique to GLP-1s — but it's a reason to report upper-right abdominal pain, particularly after fatty meals, rather than assume it's ordinary medication nausea.

Severe gastrointestinal reactions

Both labels carry a specific warning that GI adverse reactions can sometimes be severe, and both state that the medication is not recommended in patients with severe gastroparesis. Vomiting that prevents you from keeping fluids down is a reason to call, not to push through.

Low blood sugar

On its own, a GLP-1 is not a common cause of hypoglycemia in people without diabetes. Combined with insulin or an insulin secretagogue such as a sulfonylurea, the risk rises meaningfully — including severe hypoglycemia — and those doses often need to be reduced. Anyone taking these medications together needs a provider coordinating both.

Serious allergic reactions

Anaphylaxis and angioedema have been reported after marketing for both drugs. Swelling of the face, lips, tongue, or throat, or difficulty breathing, is an emergency.

Other label warnings worth knowing

• Heart rate increase. Semaglutide's label notes mean resting heart rate increases of 1–4 beats per minute versus placebo and directs that heart rate be monitored at regular intervals.
• Diabetic retinopathy complications. Relevant to patients with type 2 diabetes and a history of retinopathy, who should be monitored for progression.
• Pregnancy. Both may cause fetal harm. Semaglutide's long half-life is why its label advises discontinuing at least two months before a planned pregnancy for weight-reduction patients. Tirzepatide's label also advises patients using oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase.
• Oral medication absorption. Because both drugs delay gastric emptying, they can affect how other oral medications are absorbed — worth reviewing with any drug that has a narrow therapeutic window.

A recent labeling change worth knowing about

Warning labels are not static. As of the February 2026 revision, the Wegovy prescribing information no longer includes a “Suicidal Behavior and Ideation” warning — that section was removed. The Zepbound label, revised January 2026, still includes it and directs monitoring for depression or suicidal thoughts, with discontinuation if symptoms develop.

The practical takeaway is unchanged regardless of which label says what: significant changes in mood are worth reporting to your provider promptly, and any thoughts of self-harm warrant immediate attention. If you or someone you know is struggling, the 988 Suicide & Crisis Lifeline is available 24/7 by call or text.

Surgery, procedures, and anesthesia: have this conversation early

Both labels warn about pulmonary aspiration during general anesthesia or deep sedation, because delayed gastric emptying can leave food in the stomach longer than expected. In 2024, the American Society of Anesthesiologists and four other medical societies issued joint guidance on this, and the headline is more reassuring than most patients expect: most patients should continue their GLP-1 before elective surgery.

The guidance identifies who needs extra precautions rather than blanket discontinuation:

• People still in the dose-escalation phase — typically the first four to eight weeks — are more likely to have delayed emptying, and elective procedures are better scheduled after escalation is complete and symptoms have settled.
• Anyone currently having GI symptoms should wait for those to resolve before an elective procedure.
• People on higher doses are advised to follow a liquid-only diet for 24 hours beforehand.
• Point-of-care ultrasound can be used immediately before a procedure to assess stomach contents in the highest-risk patients.

The guidance also cautions against reflexively stopping the medication, noting the costs of interruption and warning that withholding GLP-1s only from patients with obesity could constitute bias. Both FDA labels give the same simple instruction: tell your care team about any planned surgery or procedure. Say it at scheduling, not on the morning of.

The side effects nobody warned you about

Hair loss. It appears in both labels — 3% with semaglutide and 4–5% with tirzepatide, versus about 1% on placebo. It is generally associated with rapid weight loss rather than being unique to these drugs, and adequate protein and nutrient intake is the usual first line of defense.

Loss of lean mass. Not a labeled adverse reaction, but a real consideration in any rapid weight loss. This is why we measure body composition rather than scale weight alone — an InBody body composition analysis distinguishes fat loss from muscle loss in a way a bathroom scale simply cannot.

Skin laxity. Sometimes called “Ozempic face,” though it applies to the body as well. We covered the realistic options in our article on loose skin after GLP-1 weight loss.

What happens if you stop. Discontinuation is its own topic with its own physiology, and we've written about weight regain and maintenance after stopping a GLP-1 separately.

What medical supervision actually changes

Side-effect management is not really a matter of willpower or tolerance — it's a matter of adjustment. A supervised medical weight loss program changes the experience in concrete ways: appropriate baseline lab testing before starting, screening for the contraindications above, a titration pace matched to how you're actually tolerating the medication, coordination with your other prescriptions, and objective tracking of what you're losing rather than just how much.

It also means someone knows your history when you call at week six because something doesn't feel right — which, for most patients, is the part that matters most.

Frequently asked questions

Do GLP-1 side effects go away?

For most people, digestive symptoms are worst early in treatment and after each dose increase, and ease as the body adapts to a steady dose. They are described in the clinical literature as generally mild to moderate and tending to diminish over time. Persistent symptoms are a reason to adjust the plan, not to endure it.

Which has fewer side effects, semaglutide or tirzepatide?

Their labels report different rates in separate trial programs, which are not designed for head-to-head comparison, so the honest answer is that this varies by person. Tolerability is one of several factors — along with your medical history, goals, and other medications — that belong in a conversation with a provider rather than a chart comparison.

Should I stop my GLP-1 before surgery?

Don't decide alone. Current multi-society guidance says most patients can continue before elective surgery, with specific precautions for those at higher risk. Tell your surgeon, anesthesiologist, and prescribing provider as soon as a procedure is scheduled and let them coordinate.

Is nausea a sign the medication is working?

No. Nausea is a side effect of delayed gastric emptying, not a marker of efficacy, and its absence doesn't mean the medication isn't working. Suffering through severe symptoms in the belief that it signals progress is a common and unnecessary mistake.

Can I take a GLP-1 if I have a family history of thyroid cancer?

Both medications are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 specifically. Other thyroid conditions are a different question. Bring your full family history to your consultation so it can be assessed properly.

The bottom line

GLP-1 side effects are common, mostly digestive, mostly front-loaded in the first weeks and after each dose increase, and mostly manageable with dietary adjustment, hydration, and a titration pace that respects how you feel. A short list of serious warnings — thyroid C-cell tumors, pancreatitis, gallbladder disease, severe GI reactions, hypoglycemia in combination with insulin, and serious allergic reactions — deserve prompt attention rather than patience.

Knowing which category a symptom falls into is most of the battle. Having a provider who knows your history is the rest of it.

If you're in Tarzana, Encino, Woodland Hills, Reseda, Sherman Oaks, or anywhere in the San Fernando Valley and you're considering a GLP-1 — or already on one and not sure whether what you're feeling is normal — schedule a medical weight loss consultation at Contour Medical Clinic. We'll review your history, order appropriate labs, and build a plan around how your body actually responds. You can also learn more about Contour Medical Clinic and our approach to physician-supervised care.

This article is for general educational purposes and is not medical advice. It does not replace the FDA-approved Medication Guide supplied with your prescription or guidance from your own healthcare provider. Individual results and risks vary.

Written by: Contour Medical Clinic Editorial Team